Develops generic medicines. Manufactures generic medicines. Now — the numbers.
That much dependence is a risk in itself: if this one line weakens, the whole company feels it directly.
This is an established company with proven profits.
No real growth (2% a year). Red columns mark years that ended in a loss.
The gap is $13.5B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 25.1× for every dollar of annual profit — around what a business like this usually costs.
No analyst target is on record for this company.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Trading Liquidity: The shares change hands too rarely for smooth trading.
The stock trades below its recent peak — about 11% off the top. A pullback, not a collapse.
It met or beat analyst expectations in 7 of the last 8 quarters — consistency is a promise kept.
Over the last 4 years, sales grew only 2% a year on average. At this size, speeding back up is not easy.
Getting in and out without moving the price could prove difficult. Council score: 2/10.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.